Verici Dx plc (VRCDF)
Verici Dx plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Penarth, TN, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6.9M. On trailing twelve-month figures it carries a trailing P/E of -0.45, a net margin of -223.6%. Its beta of 1.17 implies it has historically moved more than the broad market.
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Verici Dx plc is most often compared with the following Healthcare names: